Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2005 7
2006 10
2007 5
2008 3
2009 7
2010 7
2011 8
2012 8
2013 7
2014 8
2015 5
2016 6
2017 10
2018 20
2019 9
2020 20
2021 15
2022 11
2023 10
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Results by year

Filters applied: . Clear all
Page 1
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: raez le. Mol Cancer. 2024 Apr 20;23(1):78. doi: 10.1186/s12943-024-01991-3. Mol Cancer. 2024. PMID: 38643157 Free PMC article.
Genomic ancestry and cancer among Latin Americans.
Ruíz-Patiño A, Rojas L, Zuluaga J, Arrieta O, Corrales L, Martín C, Franco S, Raez L, Rolfo C, Sánchez N, Cardona AF. Ruíz-Patiño A, et al. Among authors: raez l. Clin Transl Oncol. 2024 Apr 6. doi: 10.1007/s12094-024-03415-6. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38581481
Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population.
Vallabhaneni E, Kareff SA, Barnett RM, Drusbosky LM, Dalal S, Raez LE, Santos ES, Albrecht F, Cusnir M, Rodriguez E. Vallabhaneni E, et al. Among authors: raez le. Cancers (Basel). 2024 Mar 14;16(6):1150. doi: 10.3390/cancers16061150. Cancers (Basel). 2024. PMID: 38539485 Free PMC article.
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.
Naqash AR, Floudas CS, Aber E, Maoz A, Nassar AH, Adib E, Choucair K, Xiu J, Baca Y, Ricciuti B, Alessi JV, Awad MM, Kim C, Judd J, Raez LE, Lopes G, Nieva JJ, Borghaei H, Takebe N, Ma PC, Halmos B, Kwiatkowski DJ, Liu SV, Mamdani H. Naqash AR, et al. Among authors: raez le. JCO Precis Oncol. 2024 Feb;8:e2300371. doi: 10.1200/PO.23.00371. JCO Precis Oncol. 2024. PMID: 38330261
Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis.
Motta-Guerrero R, Leon Garrido-Lecca A, Failoc-Rojas VE, Calle-Villavicencio A, Villacorta-Carranza R, Huerta-Collado Y, Torres-Mera A, Valladares-Garrido MJ, Rivera-Francia V, Carracedo C, Raez L. Motta-Guerrero R, et al. Among authors: raez l. Front Oncol. 2024 Jan 23;13:1335373. doi: 10.3389/fonc.2023.1335373. eCollection 2023. Front Oncol. 2024. PMID: 38322283 Free PMC article.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
172 results